StudyFinder

MT2020-34: A Phase 3, Open-label, Single Arm, Multicenter Study of Ravulizumab in Addition to Best Supportive Care in Pediatric Participants (from 1 month to < 18 years of age) with Thrombotic Microangiopathy (TMA) after Hematopoietic Stem Cell Transplantation (HSCT)

Status: Recruiting

Description:

To assess the efficacy of ravulizumab plus BSC in the treatment of pediatric participants with HSCT-TMA.

I'm interested

This study is NOT accepting healthy volunteers

Conditions:

Thrombotic Microangiopathy

Keywords:

Hematopoietic Stem Cell Transplant, Ravulizumab, Thrombotic Microangiopathy (TMA), Ultomiris

Contact(s): Kim Nelson - knelso62@fairview.org

Principal Investigator: Jessica Knight-Perry

Phase: Phase III

IRB Number: STUDY00011217

System ID: NCT04557735

Back